Dravet Syndrome Treatment Market By Type of Drugs (Topiramate, Levetiracetam, Zonisamide, Valproic Acid, Clobazam, Clonzepam, Stiripentol, Cannabidiol) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Dravet syndrome treatment accounted for a market value of US$ 209.2 Mn in 2018 and projected to grow at a CAGR of 11.7% during the forecast period from 2019 to 2027. The current treatment options available for Dravet syndrome target specifically the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies. In June 2018, Epidiolex (Cannabidiol) from GW Pharmaceuticals approved by USFDA specifically for Dravet syndrome. Epidiolex was followed by Fintepla (Earlier ZX008) owned by Zogenix is under approval process in the U.S. & Europe, this announcement soared shares of Zogenix by 20.5% in March 2019. Thus, overall target specific drugs are entering in the Dravet syndrome treatment horizon due to which its market growth expected to spurt from 2019 to 2027.

"Stiripentol and cannabidiol will assist the significant growth of Dravet syndrome treatment market throughout the forecast period"

In August 2018, the U.S. Food and Drug Administration (FDA) had approved stiripentol brand named as Diacomit to treat seizures associated with Dravet syndrome. Stiripentol’s market share is growing at significant rate post 2018 due to higher efficiency, safety and prolonged relief from seizures. In addition to that, cannabidiol brand named as Epidiolex manufactured by GW Research Ltd. approved in June 2018. Cannabidol is first FDA-approved drug that contains a purified drug substance derived from marijuana. Thus, overall environment of Dravet syndrome treatment market is growing significantly due to strong drug pipeline and recently approved drugs.

"North America dominated the overall global market especially due to recent drug approvals and developed diagnostic technology"

In 2017, North America dominated the market and expected to maintain its dominance throughout the forecast period due to key market drivers such as rising awareness related to neurological disorders, increasing demand for target-specific drugs to treat Dravet syndrome, and high accessibility & adaptability for recently launched drugs. During the forecast period from 2019 to 2027, Asia Pacific expected to grow significantly throughout the forecast period due to increasing awareness related to Dravet syndrome coupled with developing diagnostic technologies in neurological disease area.

Historical & Forecast Period

The Dravet syndrome treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises quantitative and qualitative data associated with the Dravet syndrome treatment market along with key market dynamics covering market opportunities, drivers, & restraints that possess its own positive and negative effects. An elaborative data of market drivers, challenges & opportunities based on country-level and regional segmentation covered in the current scope of the report. This report comprise detailed data related to the global Dravet syndrome treatment market segmented such as drug type, and geography. The report also include competitive analysis of the major companies present in Dravet syndrome treatment market including detailed data related to the competitive landscape of the market and the recent strategies & products entering the market.

The key market players involved in the Dravet syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are GW Pharmaceuticals Plc., Ovid Therapeutics, PTC Therapeutics, Inc., Epygenix Therapeutics, Inc., Zogenix, Inc., Takeda Pharmaceutical Company Ltd., Biocodex S.A., OPKO Health Inc., and Biscayne Neurotherapeutics, Inc. among others.

Key questions answered in this report

• Which is the most preferred drug to treat Dravet syndrome & Why?
• What are the recent market strategies followed by the key companies & competitive landscape of the Dravet syndrome treatment market?
• Which are the current and future major geographical markets (regions and countries) in Dravet syndrome treatment?
• Which is the largest and fastest growing Dravet syndrome treatment segment globally?
• What are the drivers, restraints, & opportunities in the Dravet syndrome treatment market?